What does the Wolverine Blend do?
It combines BPC-157 and Thymosin Beta-4, two peptides studied individually for their potential roles in tissue repair, through complementary mechanisms involving blood flow and cellular movement.
Is the Wolverine Blend FDA-approved?
No. Neither BPC-157 nor Thymosin Beta-4 has FDA approval, and their status for pharmacy compounding has changed over time as regulators continue to review available data.
How long before I may notice changes?
Responses vary considerably, and because dedicated human research on this combination doesn’t exist, there is no well-established timeline for expected results.
Is it an injection?
Yes, both components are typically administered as subcutaneous injections.
Can it be combined with other peptides?
This should always be discussed with your provider, who can evaluate your full treatment plan and goals.
Can it be combined with GLP-1 medications?
This should be discussed individually with your provider as part of your overall treatment plan.
Will I need lab work?
Your provider may recommend baseline evaluation as part of a thorough, individualized approach to this combination therapy.
Who should avoid this peptide combination?
Patients with certain active health conditions, and competitive athletes subject to anti-doping testing, should have a particularly careful conversation with their provider, as Thymosin Beta-4 is a prohibited substance in many sports contexts.
How long do patients typically remain on therapy?
Treatment length varies by individual goals, and given the evolving evidence base, your provider will help determine a reasonable, individualized plan.
Is a consultation required?
Yes. A telehealth consultation with a licensed medical provider is required before starting the Wolverine Blend or any peptide therapy at SevenHealth.